Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
Volume 0.61M
Average 0.12M
LIXT Operating Cash Flow
Cash generated by the company's core business operations during the period.
Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $1.83M (cash outflow) rose 222.1% year over year, ahead of the +47.2% change in trailing-twelve-month operating cash flow. Sequentially, it rose 68.3% from the prior quarter. Over 3 fiscal years it compounded at -12.7% a year.
Context
- Operating cash flow grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +222.1% holds above the trailing-twelve-month pace of +47.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (3.07M) USD
- Year-over-year change
- +3.0%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.07M) | +3.0% |
| FY2024 | 2024-12-31 | (3.16M) | +26.3% |
| FY2023 | 2023-12-31 | (4.29M) | +6.9% |
| FY2022 | 2022-12-31 | (4.61M) | -11.3% |
| FY2021 | 2021-12-31 | (4.14M) | — |
Operating Cash Flow vs competitors
How LIXT compares with its peers on the latest reported figures
- LIXT's LTM Mar 2026 operating cash flow of $4.33M is the smallest of the 2 companies compared; the peer median is $19.55M.
- Its year-over-year change of +47.2% is the highest of 2, against a peer median of +36.6%.
- Over three fiscal years its annual growth of -12.7% compares with a peer median of +2.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.55M | +36.6% | +2.8% | — | |
| LTM Mar 2026 | $4.33M | +47.2% | -12.7% | — | |
| Peer median (excluding LIXT) | $19.55M | +36.6% | +2.8% | — | |
Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT
Intrinsic Alpha fair value
Locked
Current Price
$7.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.